Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
Latest Information Update: 30 Dec 2022
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; Alum; AS04A; Hepatitis A vaccine inactivated
- Indications Adenocarcinoma; Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 12 Aug 2022 Planned End Date changed from 5 Jul 2022 to 31 Dec 2023.
- 12 Aug 2022 Planned primary completion date changed from 5 Jul 2022 to 31 Dec 2023.
- 13 Jun 2022 Results (n=8156) of an analysis of this long-term follow-up study from the randomised CVT Trial published in the Lancet Oncology